These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21267012)

  • 41. Impact of graphical display on the intention to undergo risk-reducing salpingo-oophorectomy and mastectomy in individuals positive for BRCA pathogenic variant.
    Choi YJ; Park Y; Park B; Chae H; Jung SY; Ryu KH; Lim MC; Park SJ; Chang YJ; Kong SY
    Sci Rep; 2024 Oct; 14(1):24281. PubMed ID: 39414838
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decision-making for Risk-reducing Salpingo-oophorectomy (RRSO) in Southeast Asian BRCA Mutation Carriers With Breast Cancer: A Qualitative Study.
    Sa'at H; Lee YK; Yoon SY; Wong SW; Woo YL; Barlow-Stewart K; Mohd Taib NA
    Int J Behav Med; 2022 Feb; 29(1):1-13. PubMed ID: 33791992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adaptation of couples living with a high risk of breast/ovarian cancer and the association with risk-reducing surgery.
    Shapira R; Turbitt E; Erby LH; Biesecker BB; Klein WMP; Hooker GW
    Fam Cancer; 2018 Oct; 17(4):485-493. PubMed ID: 29209897
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
    van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
    Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer.
    Claes E; Evers-Kiebooms G; Decruyenaere M; Denayer L; Boogaerts A; Philippe K; Legius E
    Behav Med; 2005; 31(3):93-105. PubMed ID: 16252621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
    Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with
    Roebothan A; Smith KN; Seal M; Etchegary H; Dawson L
    Curr Oncol; 2023 Oct; 30(10):9367-9381. PubMed ID: 37887578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
    J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
    Manchanda R; Burnell M; Abdelraheim A; Johnson M; Sharma A; Benjamin E; Brunell C; Saridogan E; Gessler S; Oram D; Side L; Rosenthal AN; Jacobs I; Menon U
    BJOG; 2012 Apr; 119(5):527-36. PubMed ID: 22260402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up.
    Foster C; Watson M; Eeles R; Eccles D; Ashley S; Davidson R; Mackay J; Morrison PJ; Hopwood P; Evans DG;
    Br J Cancer; 2007 Mar; 96(5):718-24. PubMed ID: 17285126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors associated with intentions for breast cancer risk management: Does risk group matter?
    Conley CC; Agnese DM; Vadaparampil ST; Andersen BL
    Psychooncology; 2019 May; 28(5):1119-1126. PubMed ID: 30889627
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.
    Tong A; Kelly S; Nusbaum R; Graves K; Peshkin BN; Valdimarsdottir HB; Wood M; McKinnon W; Garber J; McCormick SR; Jandorf L; Schwartz MD
    Psychooncology; 2015 Jan; 24(1):33-9. PubMed ID: 24839250
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
    Grann VR; Patel PR; Jacobson JS; Warner E; Heitjan DF; Ashby-Thompson M; Hershman DL; Neugut AI
    Breast Cancer Res Treat; 2011 Feb; 125(3):837-47. PubMed ID: 20644999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
    Conley CC; Kasting ML; Augusto BM; Garcia JD; Cragun D; Gonzalez BD; Kim J; Ashing KT; Knott CL; Hughes-Halbert C; Pal T; Vadaparampil ST
    Ann Surg Oncol; 2020 May; 27(5):1659-1670. PubMed ID: 31677107
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
    Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ
    Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec.
    Dorval M; Noguès C; Berthet P; Chiquette J; Gauthier-Villars M; Lasset C; Picard C; Plante M; ; ; Simard J; Julian-Reynier C
    Eur J Hum Genet; 2011 May; 19(5):494-9. PubMed ID: 21248744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
    Apostolova C; Ferroum A; Alhassan B; Prakash I; Basik M; Boileau JF; Martel K; Meterissian S; Villareal Corpuz V; Wong N; Foulkes WD; Wong SM
    Eur J Surg Oncol; 2024 Jun; 50(6):108324. PubMed ID: 38636249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.
    Salhab M; Bismohun S; Mokbel K
    BMC Womens Health; 2010 Oct; 10():28. PubMed ID: 20961453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female
    Zimovjanova M; Bielcikova Z; Miskovicova M; Vocka M; Zimovjanova A; Rybar M; Novotny J; Petruzelka L
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
    Calderon-Margalit R; Paltiel O
    Int J Cancer; 2004 Nov; 112(3):357-64. PubMed ID: 15382059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.